scispace - formally typeset
Search or ask a question
Institution

University of Colorado Denver

EducationDenver, Colorado, United States
About: University of Colorado Denver is a education organization based out in Denver, Colorado, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 27444 authors who have published 57213 publications receiving 2539937 citations. The organization is also known as: CU Denver & UCD.


Papers
More filters
Journal ArticleDOI
TL;DR: This approach requires a dual process: 1) routine developmental surveillance and screening specifically for autism to be performed on all children to first identify those atrisk for any type of atypical development, and to identify those specifically at risk for autism.
Abstract: Autism is a common disorder of childhood, affecting 1 in 500 children. Yet, it often remains unrecognized and undiagnosed until or after late preschool age because appropriate tools for routine developmental screening and screening specifically for autism have not been available. Early identification of children with autism and intensive, early intervention during the toddler and preschool years improves outcome for most young children with autism. This practice parameter reviews the available empirical evidence and gives specific recommendations for the identification of children with autism. This approach requires a dual process: 1) routine developmental surveillance and screening specifically for autism to be performed on all children to first identify those at risk for any type of atypical development, and to identify those specifically at risk for autism; and 2) to diagnose and evaluate autism, to differentiate autism from other developmental disorders.

1,077 citations

Journal ArticleDOI
Kathryn G. Roberts1, Yongjin Li, Debbie Payne-Turner1, Richard C. Harvey1, Yung-Li Yang1, Dehua Pei, Kelly McCastlain1, Li Ding2, Li Ding3, Changxue Lu3, Changxue Lu2, Guangchun Song1, Jing Ma1, Jared Becksfort, Michael Rusch, S. C. Chen1, John Easton, J. Cheng, Kristy Boggs, Natalia Santiago-Morales1, Ilaria Iacobucci1, Robert S. Fulton2, Robert S. Fulton3, Ji Wen1, Marcus B. Valentine, Cheng Cheng, Steven W. Paugh, Meenakshi Devidas4, Meenakshi Devidas5, I-Ming Chen4, S. Reshmi4, S. Reshmi6, Amy Smith6, Erin Hedlund, Pankaj Gupta, Panduka Nagahawatte, Gang Wu, Xiang Chen, Donald Yergeau, Bhavin Vadodaria, Heather L. Mulder, Naomi J. Winick7, Eric Larsen, William L. Carroll4, William L. Carroll8, Nyla A. Heerema, Andrew J. Carroll9, G. Grayson10, Sarah K. Tasian11, Andrew S. Moore12, F. Keller13, Melissa Frei-Jones14, J. A. Whitlock15, Elizabeth A. Raetz, Deborah L. White, Timothy P. Hughes16, J. M. Guidry Auvil4, Malcolm A. Smith4, Malcolm A. Smith17, Guido Marcucci7, Clara D. Bloomfield7, Krzysztof Mrózek7, Jessica Kohlschmidt7, Jessica Kohlschmidt17, Wendy Stock18, Steven M. Kornblau19, Marina Konopleva20, Elisabeth Paietta21, Ching-Hon Pui, Sima Jeha, Mary V. Relling4, William E. Evans, Daniela S. Gerhard4, Julie M. Gastier-Foster6, Julie M. Gastier-Foster4, Elaine R. Mardis, Richard K. Wilson, Mignon L. Loh22, Mignon L. Loh4, James R. Downing4, James R. Downing1, Stephen P. Hunger23, Stephen P. Hunger4, Cheryl L. Willman4, Cheryl L. Willman1, Jinghui Zhang4, Charles G. Mullighan4, Charles G. Mullighan1 
TL;DR: Ph-like ALL was found to be characterized by a range of genomic alterations that activate a limited number of signaling pathways, all of which may be amenable to inhibition with approved tyrosine kinase inhibitors.
Abstract: BACKGROUND Philadelphia chromosome–like acute lymphoblastic leukemia (Ph-like ALL) is characterized by a gene-expression profile similar to that of BCR–ABL1–positive ALL, alterations of lymphoid transcription factor genes, and a poor outcome. The frequency and spectrum of genetic alterations in Ph-like ALL and its responsiveness to tyrosine kinase inhibition are undefined, especially in adolescents and adults. METHODS We performed genomic profiling of 1725 patients with precursor B-cell ALL and detailed genomic analysis of 154 patients with Ph-like ALL. We examined the functional effects of fusion proteins and the efficacy of tyrosine kinase inhibitors in mouse pre-B cells and xenografts of human Ph-like ALL. RESULTS Ph-like ALL increased in frequency from 10% among children with standard-risk ALL to 27% among young adults with ALL and was associated with a poor outcome. Kinase-activating alterations were identified in 91% of patients with Ph-like ALL; rearrangements involving ABL1, ABL2, CRLF2, CSF1R, EPOR, JAK2, NTRK3, PDGFRB, PTK2B, TSLP, or TYK2 and sequence mutations involving FLT3, IL7R, or SH2B3 were most common. Expression of ABL1, ABL2, CSF1R, JAK2, and PDGFRB fusions resulted in cytokine-independent proliferation and activation of phosphorylated STAT5. Cell lines and human leukemic cells expressing ABL1, ABL2, CSF1R, and PDGFRB fusions were sensitive in vitro to dasatinib, EPOR and JAK2 rearrangements were sensitive to ruxolitinib, and the ETV6–NTRK3 fusion was sensitive to crizotinib. CONCLUSIONS Ph-like ALL was found to be characterized by a range of genomic alterations that activate a limited number of signaling pathways, all of which may be amenable to inhibition with approved tyrosine kinase inhibitors. Trials identifying Ph-like ALL are needed to assess whether adding tyrosine kinase inhibitors to current therapy will improve the survival of patients with this type of leukemia. (Funded by the American Lebanese Syrian Associated Charities and others.)

1,077 citations

Journal ArticleDOI
TL;DR: Science Inquiry provides a forum to facilitate the ongoing process of questioning and evaluating practice, presents informed practice based on available data, and innovates new practices through research and experimental learning.
Abstract: Column Editor: Lauren Clark Scientific Inquiry provides a forum to facilitate the ongoing process of questioning and evaluating practice, presents informed practice based on available data, and innovates new practices through research and experimental learning.

1,075 citations

Journal ArticleDOI
TL;DR: The guidelines were developed jointly by the American Society of Health-System Pharmacists (ASHP), the Infectious Diseases Society of America (IDSA), the Surgical Infection Society (SIS), and the Society for Healthcare Epidemiology (SHEA) as mentioned in this paper.
Abstract: These guidelines were developed jointly by the American Society of Health-System Pharmacists (ASHP), the Infectious Diseases Society of America (IDSA), the Surgical Infection Society (SIS), and the Society for Healthcare Epidemiology of America (SHEA). This work represents an update to the

1,074 citations

Journal ArticleDOI
08 Jun 2011-JAMA
TL;DR: Among women in the general US population, simultaneous screening with CA-125 and transvaginal ultrasound compared with usual care did not reduce ovarian cancer mortality.
Abstract: Context Screening for ovarian cancer with cancer antigen 125 (CA-125) and transvaginal ultrasound has an unknown effect on mortality. Objective To evaluate the effect of screening for ovarian cancer on mortality in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Design, Setting, and Participants Randomized controlled trial of 78 216 women aged 55 to 74 years assigned to undergo either annual screening (n = 39 105) or usual care (n = 39 111) at 10 screening centers across the United States between November 1993 and July 2001. Intervention The intervention group was offered annual screening with CA-125 for 6 years and transvaginal ultrasound for 4 years. Participants and their health care practitioners received the screening test results and managed evaluation of abnormal results. The usual care group was not offered annual screening with CA-125 for 6 years or transvaginal ultrasound but received their usual medical care. Participants were followed up for a maximum of 13 years (median [range], 12.4 years [10.9-13.0 years]) for cancer diagnoses and death until February 28, 2010. Main Outcome Measures Mortality from ovarian cancer, including primary peritoneal and fallopian tube cancers. Secondary outcomes included ovarian cancer incidence and complications associated with screening examinations and diagnostic procedures. Results Ovarian cancer was diagnosed in 212 women (5.7 per 10 000 person-years) in the intervention group and 176 (4.7 per 10 000 person-years) in the usual care group (rate ratio [RR], 1.21; 95% confidence interval [CI], 0.99-1.48). There were 118 deaths caused by ovarian cancer (3.1 per 10 000 person-years) in the intervention group and 100 deaths (2.6 per 10 000 person-years) in the usual care group (mortality RR, 1.18; 95% CI, 0.82-1.71). Of 3285 women with false-positive results, 1080 underwent surgical follow-up; of whom, 163 women experienced at least 1 serious complication (15%). There were 2924 deaths due to other causes (excluding ovarian, colorectal, and lung cancer) (76.6 per 10 000 person-years) in the intervention group and 2914 deaths (76.2 per 10 000 person-years) in the usual care group (RR, 1.01; 95% CI, 0.96-1.06). Conclusions Among women in the general US population, simultaneous screening with CA-125 and transvaginal ultrasound compared with usual care did not reduce ovarian cancer mortality. Diagnostic evaluation following a false-positive screening test result was associated with complications. Trial Registration clinicaltrials.gov Identifier: NCT00002540

1,073 citations


Authors

Showing all 27683 results

NameH-indexPapersCitations
Matthew Meyerson194553243726
Charles A. Dinarello1901058139668
Gad Getz189520247560
Gordon B. Mills1871273186451
Jasvinder A. Singh1762382223370
David Haussler172488224960
Donald G. Truhlar1651518157965
Charles M. Perou156573202951
David Cella1561258106402
Bruce D. Walker15577986020
Marco A. Marra153620184684
Thomas E. Starzl150162591704
Marc Humbert1491184100577
Rajesh Kumar1494439140830
Martin J. Blaser147820104104
Network Information
Related Institutions (5)
University of Pittsburgh
201K papers, 9.6M citations

98% related

University of California, San Francisco
186.2K papers, 12M citations

97% related

University of North Carolina at Chapel Hill
185.3K papers, 9.9M citations

97% related

Duke University
200.3K papers, 10.7M citations

97% related

University of Pennsylvania
257.6K papers, 14.1M citations

96% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20241
202383
2022358
20213,830
20203,913
20193,632